Mylan Inc.

  • 3 Basic Reasons Medical Marijuana Stocks Are Doomed For Failure

    By Nickey Friedman - August 31, 2013 | Tickers: BMY, MDBX, MJNA, MRK, MYL, PFE

    We've all seen it. Medical marijuana stocks are flying into the stratosphere as a new industry in America is born. What's not to get excited about? There are only a handful of public companies breaking into this new, multi-billion dollar industry with high hopes and expectations of giant windfalls in profits for all. As this article explains, nobody needs to sell the industry -- it sells itself! It sells more »

  • Why I Like Generic Pharmaceuticals

    By Daniel Jennings - August 12, 2013 | Tickers: RDY, MYL, PRGO

    I don’t like traditional pharmaceutical houses as either a business or an investment. I think the way they try to gouge customers with no choice—sick people—with high prices is just plain wrong. The high research and development costs, sleazy marketing practices, and abuse of the patent system to needlessly jack up prices put me off.

    Yet there’s one area of the drug business I like: generic more »

  • Can the Rise of the Global Old Help You Retire?

    By Paul Sangrey - August 6, 2013 | Tickers: MYL, NVS, PFE, TEVA

    Big Pharma is in trouble. U.S. pharmaceutical revenue fell for the first time on record last year because so many drugs came off of their patents, what was called as the patent cliff. In real terms, revenue fell by 3.5% according to the New York Times . Furthermore, another smaller but still notable patent cliff is coming in 2015.

    So, at first glance, now doesn't seem to be more »

  • Billionaire John Paulson’s Long-Term Stock Picks

    By Meena Krishnamsetty - August 2, 2013 | Tickers: BAC, MGM, MYL

    Insider Monkey tracks quarterly 13F filings from hundreds of hedge funds, including billionaire John Paulson’s Paulson & Co. We’ve found in our work researching investment strategies that the most popular small cap stocks among hedge funds earn an average excess return of 18 percentage points per year (learn more about our small cap strategy), and it can be useful to track hedge fund activity over time as well.

    For more »

  • Great Pipelines, Unimpressive Fundamentals

    By Harriet Tramer - July 25, 2013 | Tickers: AMGN, GILD, MYL

    Biotechnology medicine manipulates the genetic material of living organisms to produce pharmaceuticals, which in many instances are designed to combat diseases once considered untreatable. So, they should enjoy an expanding customer base; as our country ages increasingly more people will benefit from life saving medical advances.

    But does that necessarily mean companies, such as Amgen (NASDAQ: AMGN), Gilead Science (NASDAQ: GILD) and Mylan (NASDAQ: MYL), which are heavily involved in more »

  • How Acquisitions Mean Growth for These Generic Drug Makers

    By Madhukar Dubey - July 22, 2013 | Tickers: ACT, MYL, WCRX

    The global generic drug industry will reach $169 billion in 2014 with a compounded annual growth rate of 15% over five years. The patent expiration of branded drugs opens the door for generic versions, fueling the growth of the generic drug industry. Additionally, the companies in this industry are adopting strategies to maintain growth momentum and investor confidence, including focusing on emerging markets and acquisitions.

    This article analyzes three companies more »

  • Generics Set to Soar

    By Marshall Hargrave - July 22, 2013 | Tickers: ACT, HSP, MYL, TEVA

    IMS Health pegs the worldwide generic drug market at an impressive $240 billion, which should only grow over the long-term as a large number of branded drugs lose patent protection -- pushing the total generic drug market to over $420 billion in 2016. 

    Other key factors driving generic market growth will be a rapidly aging population and the healthcare reform in he U.S., which will give more people access to more »

  • Warner Chilcott: Should You Buy Joel Greenblatt's Latest Pick?

    By Zarr Pacificador - June 13, 2013 | Tickers: ACT, MYL, VRX, WCRX

    Searching for potential stock investments can be a daunting task. With so many stocks to choose from – more than 2,300 listed on the NYSE and around 2,800 on Nasdaq – how do you find good ideas?

    One way, and the probably the most common way, is the use of stock screens. With information on publicly listed companies increasingly available online, it is easier now to come up with a more »

  • Is This Hurting Healthcare Company Priced for a Recovery?

    By Bob Chandler - June 13, 2013 | Tickers: ACT, HSP, MYL

    Nothing interests a value investor more than bad news. Where there's a lack of enthusiasm, there's usually a cheap stock. Hospira (NYSE: HSP), a leading manufacturer of generic specialty injectable drugs and infusion pumps, looked a likely candidate. Since mid-2010, the company has delivered a litany of bad news but instead of a depressed bargain the share's look surprisingly fit.

    A chronic case of unsettling news

    The more »

  • Undervalued Teva Must Enter New Markets

    By David Gould - June 12, 2013 | Tickers: JNJ, MYL, TEVA

    Generic producers are often regarded as the safer players within BioPharma. They take existing drugs that have fallen off patents, tweak them a bit, and release a product into the market. R&D expenses are kept low, and business is relatively predictable.

    Similarly, medical device companies have lower risk profiles by virtue of their more predictable operating model. However, they both have experienced their own problems and are not resting more »

  • Which Generic Drugmaker Is Your Best Buy Today?

    By Brendan O'Boyle - June 6, 2013 | Tickers: ACT, MYL, PFE, TARO

    Generic-drug makers have considerable tailwinds, making their outperformance in the past year unsurprising.  However, most companies within this sub-industry are both cheap and relatively unknown -- a combination which bodes well for investors. Here, we'll review three generic-drug makers that still trade at appealing valuations.

    How the generics game works

    Prescription drugs are split into two categories: generic and brand-name. Pharmaceutical companies develop their products through a laborious and risky more »

  • Is Actavis a Buy at This Price?

    By Kanak Kanti - May 31, 2013 | Tickers: ACT, MYL, TEVA, WCRX

    Actavis (NYSE: ACT), the largest generic drug company in the US, just got even bigger. In a deal valued at $8.5 billion, Actavis has agreed to buy the Irish women’s healthcare company, Warner Chilcott (NASDAQ: WCRX) to create what would be the third largest specialty pharmaceutical company in the US market.

    Investors naturally want to know what is in it for them - should they hoard up on the more »

  • Two Stocks That Double Your Chances For Big Gains

    By Ken McGaha - May 30, 2013 | Tickers: IPXL, MYL, QCOR

    Virtually every investor is quite familiar with the names of big pharmaceutical giants such as Glaxosmithkline, Eli Lilly, and Abbott Labs and the fortunes that have been made by investors in these enormously successful businesses. What many investors fail to spend time considering is that a much of the growth of these large businesses came from buyouts of smaller faster growing companies within the pharmaceutical industry that were priced cheaply more »

  • Could Warner Chilcott Receive a Higher Bid?

    By Anh HOANG - May 30, 2013 | Tickers: ACT, MYL, WCRX

    Recently, Actavis (NYSE: ACT) announced that it would acquire Warner Chilcott (NASDAQ: WCRX) for around $8.5 billion in total consideration. Since the beginning of the year, Warner Chilcott has risen from around $12 per share to nearly $20 per share. Is a $5 billion deal a fair offering price for Warner Chilcott? Let’s find out.

    Actavis and Warner Chilcott’s snapshot

    Actavis provides 250 generic pharmaceutical product families more »

  • If You Can't Beat 'Em, Join 'Em

    By John Timmes - May 20, 2013 | Tickers: DLPH, MGM, MYL

    While emulating the investment portfolio of a hedge fund titan is not realistic, examining their investments can lead to interesting conversations and potential investment ideas. In this article, I look at two stocks from the top holdings of Paulson & Company, the hedge fund group run by the legendary investor John Paulson.

    MGM Resorts International

    MGM (NYSE: MGM) owns and operates 15 casino resorts in the United States and the MGM more »

  • This Potential Merger Is Worth a Look

    By Anh HOANG - May 3, 2013 | Tickers: ACT, MYL, VRX

    In the pharmaceutical industry, the potential merger between Valeant Pharmaceuticals (NYSE: VRX) and Actavis (NYSE: ACT) is getting a lot of attention. However, merger talks have been put on hold due to the disagreement on the price between the parties. Since the beginning of the year, the two companies’ shares have appreciated strongly. While Valeant has gained more than 27%, Actavis has appreciated nearly 23%.

    Should investors consider these two more »

  • Teva Pharmaceuticals: Will the Transition Be Effective?

    By Shas Dey - April 22, 2013 | Tickers: ACT, MYL, TEVA | Editor's Choice

    Teva (NYSE: TEVA), a pharmaceuticals company that makes money off of branded drugs as well as generics, is an interesting example of a company in transition. Investors are currently not well-favored towards Teva given the uncertainty looming over its drug pipeline and the consequences of the new strategy being implemented by its newly appointed CEO, but there is merit in the changes being carried out at this firm.

    Copaxone patent more »

  • Teva Pharmaceuticals – will the transition be effective?

    By Shas Dey - April 16, 2013 | Tickers: ACT, MYL, TEVA

    Teva (NYSE: TEVA), a pharmaceuticals company that makes money off of branded drugs as well as generics, is an interesting example of a company in transition. Investors are currently not well-favored towards Teva given the uncertainty looming over its drug pipeline and the consequences of the new strategy being implemented by its newly appointed CEO, but there is merit in the changes being carried out at this firm.

    Copaxone patent more »

  • Actavis Profits Decrease As Acquisition Takes Toll

    By Jacob Wolinsky - March 15, 2013 | Tickers: ACT, MYL, TEVA

    ValueWalk.com was started in January 2010, with a focus on value investing and value investors. As the site has grown, the scope has expanded. ValueWalk is now a news site with a team of global reporters covering all breaking financial news with an emphasis on value investing, hedge funds, large asset managers, Tech news, Business news.  The site contains archives of famous investors, and many investor resource pages.

    The site is famous among the value investing community as one of the best sites for evergreen and new content. ValueWalk has gained popularity among all circles for its breaking stories on hedge funds, and investigative reports on investments  by major funds.

    You can also check out ValueWalk Premium, where we analyze liquid stocks, which have little to no analyst coverage.

  • Mylan in a Whole Different League?

    By Jacob Wolinsky - March 13, 2013 | Tickers: AVNR, MNTA, MYL

    ValueWalk.com was started in January 2010, with a focus on value investing and value investors. As the site has grown, the scope has expanded. ValueWalk is now a news site with a team of global reporters covering all breaking financial news with an emphasis on value investing, hedge funds, large asset managers, Tech news, Business news.  The site contains archives of famous investors, and many investor resource pages.

    The site is famous among the value investing community as one of the best sites for evergreen and new content. ValueWalk has gained popularity among all circles for its breaking stories on hedge funds, and investigative reports on investments  by major funds.

    You can also check out ValueWalk Premium, where we analyze liquid stocks, which have little to no analyst coverage.

  • Page 1 of 3